Trials / Completed
CompletedNCT00437125
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duloxetine hydrochloride | Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2007-02-19
- Last updated
- 2010-09-08
- Results posted
- 2010-08-16
Locations
13 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00437125. Inclusion in this directory is not an endorsement.